Related Experiment Video

Updated: Aug 6, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Preclinical and clinical development of novel agents that target the protein kinase C family

Maria Serova1, Aïda Ghoul, Karim A Benhadji

  • 1U716, Hopital Saint-Louis, Paris, France

Seminars in Oncology
|August 8, 2006
PubMed

Insights

Protein Kinase C (PKC) isoenzymes are key in cancer cell signaling and drug resistance. Modulating PKC activity offers a promising strategy for novel anticancer therapeutics and overcoming chemotherapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The Protein Kinase C (PKC) family has over 12 isoenzymes involved in cell signaling.
  • PKC isoenzymes regulate critical cellular processes including proliferation, cell cycle, apoptosis, invasion, differentiation, and senescence in cancer and endothelial cells.

Purpose of the Study:

  • To review the role of PKC in chemotherapeutic resistance.
  • To discuss the implications of PKC modulation in cancer treatment.
  • To explore the potential of novel PKC inhibitors in molecular cancer therapeutics.

Main Methods:

  • Literature review of preclinical and clinical data.
  • Analysis of PKC's role in signal transduction pathways.
  • Evaluation of PKC inhibitors and activators in cancer therapy.

Main Results:

  • PKC isoenzymes significantly influence tumor growth, angiogenesis, and multi-drug resistance.
  • Targeting specific PKC isoenzymes can impact cancer cell behavior and response to chemotherapy.
  • First-generation PKC modulators show potential but further research is ongoing.

Conclusions:

  • PKC isoenzymes are attractive targets for developing new anticancer drugs.
  • Modulating PKC activity may enhance the efficacy of existing chemotherapeutic regimens.
  • Recent advancements in PKC inhibitors offer new avenues for molecular cancer therapeutics.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...